Paradigm Biocapital Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Paradigm Biocapital Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-477,585	Closed	-$54.3M	–	30
2022 Q4	$54.3M	Buy	477,585 +126,180	+36%	+$10.5M	6.38%	4
2022 Q3	$21.7M	Buy	+351,405	New	+$24.6M	2.9%	16
2022 Q2	–	Sell	-136,243	Closed	-$14.3M	–	30
2022 Q1	$14.3M	Buy	+136,243	New	+$13.3M	3.79%	11

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Paradigm Biocapital Advisors's HZNP Position: Q1 2023 in Review

Paradigm Biocapital Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2023, closing a stake of 477,585 shares — an estimated $54.3M sold.

Paradigm Biocapital Advisors first reported a position in HZNP in Q1 2022 and held it in 3 quarters. The position peaked at $54.3M in Q4 2022. 553 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

Paradigm Biocapital Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Paradigm Biocapital Advisors sold 477,585 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2023, an estimated $54.3M.
Paradigm Biocapital Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2022 and held it in 3 quarters.
Paradigm Biocapital Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $54.3M in Q4 2022.
553 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on Paradigm Biocapital Advisors's 13F filing for Q1 2023, filed 15 May 2023.